Skip to main content
. 2021 Feb 1;113(8):1005–1016. doi: 10.1093/jnci/djab004

Figure 4.

Figure 4.

Efficacy analyses in patient subgroups defined by tumor-infiltrating CD8+ T cells. A) Correlation between CD8 (as a percentage of tumor center) and PD-L1 IC as a percentage of tumor area (left); distribution of CD8 (log2) by PD-L1 IC status (right). B) Overlap of CD8+ (≥0.5%) with PD-L1 IC+. C) PFS and OS Kaplan-Meyer survival curves by CD8 status (<0.5% vs ≥0.5%) in P+nP arm. D) PFS and OS Kaplan-Meier curves for CD8+ in A+nP or P+nP arms. E) Forest plots of PFS and OS in CD8- and PD-L1 IC-defined patient subgroups. Analyses adjusted for prior taxane treatment and liver metastases. All P values are for descriptive purposes only. A = atezolizumab; BEP = biomarker-evaluable population; CI = confidence interval; HR = hazard ratio; IC = tumor-infiltrating immune cells; IC+ = PD-L1 ≥ 1% on IC; IC− = PD-L1 < 1% on IC; IQR= interquartile range; nP = nab-paclitaxel; OS = overall survival; P = placebo; PD-L1 = programmed death-ligand 1; PFS = progression-free survival; r = Spearman correlation index.